Caitlin M Tilsed
Overview
Explore the profile of Caitlin M Tilsed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Principe N, Phung A, Stevens K, Elaskalani O, Wylie B, Tilsed C, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39343508
Background: Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein/ligand 1 (PD-1/PD-L1) are approved for treatment of multiple cancer types. Chemotherapy is...
2.
Chin W, Zemek R, Tilsed C, Forrest A, Fear V, Forbes C, et al.
Sci Data
. 2024 May;
11(1):448.
PMID: 38702329
Time-critical transcriptional events in the immune microenvironment are important for response to immune checkpoint blockade (ICB), yet these events are difficult to characterise and remain incompletely understood. Here, we present...
3.
Tilsed C, Sadiq B, Papp T, Areesawangkit P, Kimura K, Noguera-Ortega E, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(13):e2319856121.
PMID: 38513098
The use of lipid nanoparticles (LNP) to encapsulate and deliver mRNA has become an important therapeutic advance. In addition to vaccines, LNP-mRNA can be used in many other applications. For...
4.
Tilsed C, Orozco Morales M, Zemek R, Gordon B, Piggott M, Nowak A, et al.
BMC Cancer
. 2024 Feb;
24(1):203.
PMID: 38350880
Background: Chemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard...
5.
Tilsed C, Principe N, Kidman J, Chin W, Orozco Morales M, Zemek R, et al.
Cell Rep
. 2022 Dec;
41(13):111874.
PMID: 36577370
While chemotherapy remains the first-line treatment for many cancers, it is still unclear what distinguishes responders from non-responders. Here, we characterize the chemotherapy-responsive tumor microenvironment in mice, using RNA sequencing...
6.
Boulter J, Orozco Morales M, Principe N, Tilsed C
Immunol Cell Biol
. 2022 Aug;
101(2):97-103.
PMID: 36006827
Kindness in Science is a grassroots initiative to establish a scientific community built on diversity, respect and well-being, which would ultimately lead to happier scientists and better scientific outcomes. We...
7.
Zemek R, Chin W, Fear V, Wylie B, Casey T, Forbes C, et al.
Nat Commun
. 2022 Aug;
13(1):4895.
PMID: 35986006
The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the...
8.
Tilsed C, Fisher S, Nowak A, Lake R, Lesterhuis W
Front Oncol
. 2022 Aug;
12:960317.
PMID: 35965519
Chemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response remains limited. The diverse response of cancer patients to chemotherapy has...
9.
Principe N, Aston W, Hope D, Tilsed C, Fisher S, Boon L, et al.
Front Immunol
. 2022 May;
13:872295.
PMID: 35634282
Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer...
10.
Tilsed C, Casey T, de Jong E, Bosco A, Zemek R, Salmons J, et al.
Front Oncol
. 2022 Apr;
12:849793.
PMID: 35402250
With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others...